· investment-strategies · 4 min read
Boston & Cambridge Startups We Cover in 2026: Boltz, OpenEvidence, Whoop, GCTx
As of July 2026, directory companies we can honestly place in Boston–Cambridge or Greater Boston — plus related biotech coverage tied to Boston capital with HQ labeled elsewhere.
Short answer (as of July 2026): Curated Boston–Cambridge startups in our directory include Boltz, OpenEvidence, Whoop, GC Therapeutics, Dyno Therapeutics, ROME Therapeutics, Asimov, and Curie.Bio. The table below includes additional Greater Boston companies we index with HQ evidence.
City hub: /vc/boston-cambridge · Funds: Boston–Cambridge VC firms 2026 · Directory: /directory
What this hub is (and is not)
| This page is… | This page is not… |
|---|---|
A coverage map of /startup/ pages with Boston-area HQ evidence | A “top startups” ranking with invented valuations |
| Curated IDs wired on /vc/boston-cambridge | Every Kendall Square company |
| Honest about HQ elsewhere in the related section | Fake Cambridge addresses on national stubs |
Curated startups (city hub IDs)
| Company | What they do | Stage / status | Notable capital | Profile |
|---|---|---|---|---|
| Boltz | MIT-origin AI protein / biomolecular models | Seed | a16z | /startup/boltz |
| OpenEvidence | Clinical evidence AI for physicians | Growth | General Catalyst | /startup/openevidence |
| Whoop | Wearable performance / recovery | Growth | Spark, a16z | /startup/whoop |
| GC Therapeutics | iPSC programming for cell therapy | Series A | a16z, Pear VC | /startup/gc-therapeutics |
| Dyno Therapeutics | AI-designed AAV capsids | Acquired (Novo, 2023) | a16z | /startup/dyno-therapeutics |
| ROME Therapeutics | Repeatome biology | Acquired (2026 press) | a16z, ARCH | /startup/rome-therapeutics |
| Asimov | Genetic circuit design for biologics | Series B | General Catalyst, F-Prime | /startup/asimov |
| Curie.Bio | Hybrid seed + drug-discovery ops platform | Platform | a16z, ARCH | /startup/curiebio |
Boston–Cambridge & Greater Boston — extended coverage
HQ notes use public citations (company sites, CB Insights, press) because most startup JSON files omit an hq field. Where we say “commonly cited,” that is intentional.
| Startup | One-liner | Stage / status | HQ evidence | Notable investors (directory) | Profile |
|---|---|---|---|---|---|
| Boston Metal | Molten Oxide Electrolysis for lower-emission critical metals / steel pathways | Other / private; $75M deploy raise (May 2026 coverage) | Woburn, MA (Greater Boston) | Not fully mapped on startup JSON; see funding note | /startup/boston-metal |
| Boltz | MIT-origin PBC applying open AI protein / biomolecular models to lab use | Seed / private | Boston / Cambridge (MIT Jameel Clinic origin) | Andreessen Horowitz | /startup/boltz |
| Ventus Therapeutics | Structure-based small-molecule discovery (ReSOLVE) | Growth / private | Waltham, MA | Andreessen Horowitz | /startup/ventus-therapeutics |
| ROME Therapeutics | Repeatome biology for cancer / autoimmune targets | Series B / private (press: acquired by Pretzel Therapeutics Jan 2026) | Boston, MA | Andreessen Horowitz, ARCH Venture Partners | /startup/rome-therapeutics |
| IDRx | Precision oncology (KIT / GIST focus in public materials) | Acquired (GSK deal in public coverage) | Plymouth, MA (Boston-area; Cambridge presence cited) | Andreessen Horowitz | /startup/idrx |
| GC Therapeutics | iPSC programming (TFome) for scalable cell therapy — Church-lab origin | Series A / private | Cambridge, MA | Andreessen Horowitz, Pear VC | /startup/gc-therapeutics |
| Curie.Bio | Hybrid seed vehicle + drug-discovery ops for pre–Series A therapeutics | Other / private (platform) | Boston, MA | Andreessen Horowitz, ARCH Venture Partners | /startup/curiebio |
| Alpha-9 Oncology | Clinical-stage targeted radiopharmaceuticals | Growth / private | Boston, MA HQ commonly cited; Vancouver ops | Andreessen Horowitz, General Catalyst | /startup/alpha-9-oncology |
| Anagram Therapeutics | Oral enzyme / malabsorption therapeutics (directory cites large 2026 raise) | Other / private | Natick, MA (MetroWest) | Investor list thin on JSON — treat as coverage stub for syndicate detail | /startup/anagram-therapeutics |
| Nava Therapeutics | Next-gen LNP delivery systems | Series A / private | Cambridge, MA | Andreessen Horowitz, F-Prime Capital | /startup/nava-therapeutics |
| Mentari Therapeutics | Anti-PACAP / CGRP migraine biologics | Growth / private | Waltham, MA | Andreessen Horowitz | /startup/mentari-therapeutics |
How to read this coverage
- Directory map of companies we index with Boston–Cambridge evidence — not a “top startups” ranking (no invented valuations).
- Biotech-skewed because that is what we have ingested; Boston SaaS/cyber names are mostly still coverage gaps.
- Status matters: IDRx is acquired; ROME has acquisition press — useful as cluster evidence, not active raise targets.
Related directory biotech — HQ elsewhere
Same /startup/ IDs, often sharing syndicates with Boston-active capital (a16z Bio, ARCH). Not claimed as local HQs.
| Startup | HQ / label | Profile |
|---|---|---|
| Hera — AI senior-care coordination | New York, NY (BCV has a Boston office; company is NYC) | /startup/hera |
| Gate Bioscience — Molecular Gate medicines | Brisbane, CA | /startup/gate-bioscience |
| Cartography Biosciences — antigen atlas / IO | SF Bay (commonly cited) | /startup/cartography-biosciences |
| Ona Therapeutics — ADCs for resistant cancers | Barcelona | /startup/ona-therapeutics |
| Rezo Therapeutics — disease-network mapping | San Francisco (UCSF-origin) | /startup/rezo-therapeutics |
| Ollin Bio — retinal biologics | Austin, TX | /startup/ollin-bio |
| Mana Bio — ML LNPs | HQ not verified as Boston | /startup/mana-bio |
| Inceptive — AI-designed mRNA | Bay Area commonly cited | /startup/inceptive |
| Patch Biosciences, Phylo, Santa Ana Bio, Orchestra Bio | HQ unclear / stubs — gap, not a city claim | linked IDs |
Worked example (illustrative)
Setup: A Cambridge AI-biology team spins out of an MIT lab with open models and two pharma design partners.
Move: They raise seed from a16z (Boltz pattern), then Series A from F-Prime or Atlas when IND-enabling work is scoped.
Punch: Boston rewards science + process fit — the syndicate mixes national seed with local creation/join-in specialists.
When this list misleads you
- You treat every a16z biotech name as Boston HQ — check the related section.
- You pitch acquired companies (IDRx, Dyno, ROME) as active raise targets.
- You skip the fund hub and blast every GP with one deck.
- You expect complete Boston SaaS coverage — our JSON is biotech-heavy today.
Coverage gaps
- Flagship-class creation companies named in the playbook without matching
/startup/pages here - Classic Boston B2B SaaS / cyber under-indexed vs biotech
- Thin investor graphs on some local names (e.g. Anagram)
Next steps
Sources
- Startup profiles linked above
- HQ corroboration: Boston Metal/Woburn; Boltz MIT/Boston; Ventus Waltham; ROME Boston; IDRx Plymouth; GCTx Cambridge; Curie.Bio Boston; Alpha-9 Boston+Vancouver; Anagram Natick; Nava Cambridge; Mentari Waltham; Gate Brisbane CA; Ona Barcelona; Ollin Austin; Hera NYC
- Boston Metal funding note · biotech playbook
- boston
- cambridge
- venture-capital
- +2 more